Advertisement

ASO Author Reflections: Perioperative Genomic Profiles and Prognosis of Peripheral and Perihepatic Circulating Tumor DNA in Patients with Colorectal Liver Metastases

  • Raja R. Narayan
  • T. Peter KinghamEmail author
ASO Author Reflections
  • 44 Downloads

Notes

Disclosure

Raja R. Narayan and T. Peter Kingham have no conflicts of interest to disclose.

References

  1. 1.
    Garlan F, Laurent-Puig P, Sefrioui D, et al. Early Evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017;23(18):5416–5425.CrossRefGoogle Scholar
  2. 2.
    Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.CrossRefGoogle Scholar
  3. 3.
    Gagniere J, Dupre A, Gholami SS, et al. Is hepatectomy justified for BRAF mutant colorectal liver metastases? A multi-institutional analysis of 1497 patients. Ann Surg. Epub 10 Jul 2018.  https://doi.org/10.1097/sla.0000000000002968.
  4. 4.
    Connor AA, McNamara K, Al-Sukhni E, et al. Central, but not peripheral, circulating tumor cells are prognostic in patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2016;23(7):2168–2175.CrossRefGoogle Scholar
  5. 5.
    Narayan RR, Goldman DA, Gonen M, et al. Peripheral circulating tumor DNA detection predicts poor outcomes after liver resection for metastatic colorectal cancer. Ann Surg Oncol. Epub 31 Jan 2019.  https://doi.org/10.1245/s10434-019-07201-5.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Surgery, Hepatopancreatobiliary ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of SurgeryStanford University School of MedicineStanfordUSA

Personalised recommendations